Search
Search Results
##search.searchResults.foundPlural##
-
MIR-140 TARGETS LNCRNA DNAJC3-AS1 TO SUPPRESS CELL PROLIFERATION IN ACUTE MYELOID LEUKEMIA AML proliferation and MIR-140 LNCRNA DNAJC3-AS1 target.
1187PDF: 583HTML: 206 -
UPDATE ON THE LABORATORY DIAGNOSIS OF INVASIVE FUNGAL INFECTIONS
2346PDF: 1384HTML: 1973 -
Skin Manifestations associated with Mantle cell Lymphoma: a case report
1524PDF: 750HTML: 2121Untitled: 214Untitled: 188Untitled: 191Untitled: 193Untitled: 193 -
ASSOCIATION OF VDBP RS4701 VARIANT, BUT NOT VDR/RXR-? OVER-EXPRESSION WITH BONE MINERAL DENSITY IN PEDIATRIC ?-THALASSEMIA PATIENTS Vitamin D metabolic axis and BMD in ?-thalassemia
1185PDF: 715HTML: 176 -
PERIOPERATIVE MANAGEMENT OF SICKLE CELL DISEASE: A NARRATIVE REVIEW
7926PDF: 3224HTML: 1212 -
How I treat acute and persistent sickle cell pain
1888PDF: 1106HTML: 475 -
ULTRASOUND AS FIRST LINE STEP IN ANAEMIA DIAGNOSTICS
1355PDF: 875HTML: 1797 -
Correlation to FVIII:C in two thrombin generation tests: TGA-CAT and INNOVANCE ETP
2203PDF: 771HTML: 849Figure 2: 211Figure 1: 164 -
COULD PLASMA GLUCOSE (PG) INCREMENT (PG %) EXPAND THE CLINICAL WEIGHT OF OGTT? PRELIMINARY FINDINGS IN 19 TDT PATIENTS (Β-TDT) WITH NORMAL GLUCOSE TOLERANCE Plasma glucose (PG) increment (PG %) and pancretic β-cell dysfunction in thalassemia
674PDF: 485HTML: 34 -
REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy
1536PDF: 596HTML: 180 -
ANTIFUNGAL PROPHYLAXIS IN IMMUNOCOMPROMISED PATIENTS
4256PDF: 1361HTML: 2030 -
ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS
1655PDF: 798HTML: 926cover letter: 261 -
FASTING PLASMA GLUCOSE LEVELS WITHIN THE HIGH NORMAL RANGE ARE ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF FUTURE DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β THALASSEMIA: A DECADE-LONG MULTICENTER RETROSPECTIVE ANALYSIS Higher normal fasting plasma glucose and glucose dysregulation in β- thalassemia
607PDF: 212Html: 28 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1493PDF: 926HTML: 215 -
DECREASED CD10 EXPRESSION IN THE BONE MARROW NEUTROPHILS OF HIV POSITIVE PATIENTS
1223PDF: 853HTML: 1107Coverletter: 189 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2133PDF: 1562HTML: 255 -
Severe immune thrombocytopenia (ITP) following SARS-CoV-2 mRNA vaccine in a girl on immunosuppressive treatment and in prolonged stable phase of ITP. immune thrombocytopenia following mRNA vaccine
2086PDF: 544HTML: 1134 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2129PDF: 1452HTML: 258 -
MANAGEMENT OF HBV INFECTION DURING IMMUNOSUPPRESIVE TREATMENT
823PDF: 485HTML: 1292 -
MODULATING EFFECT OF THE ?158 G? (C?T) XMN-1 POLYMORPHISM IN INDIAN SICKLE CELL PATIENTS
1486PDF: 879HTML: 1419Table: 188 -
Respiratory function in pediatric African SCA patients underwent bone marrow transplantation
2104PDF: 751HTML: 1030Spirometry in SCA patients before transplant: 198Spirometry in SCA patients post transplant: 178 -
GROUP-BASED TRAJECTORY MODELING OF PLATELET IN PATIENTS WITH APLASTIC ANEMIA: A STUDY BASED ON THE MIMIC DATABASE
973PDF: 977Suppl. Files: 627HTML: 115 -
“Hemolysis, or not Hemolysis, that is the question”. Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency. Hemolysis by Hemolysis and G6PD deficiency.
1241PDF: 970HTML: 322







